Business Context and Reporting Period
This Form 8-K Current Report was filed by Corbus Pharmaceuticals Holdings, Inc. on May 19, 2026, with the earliest event reported on May 21, 2026. The filing primarily addresses the entry into a material definitive employment agreement and the appointment of a new officer.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and corporate governance events.
Material Changes and Events
- Appointment of Chief Business Officer: The Company entered into a two-year employment agreement with Nishant Saxena, effective May 21, 2026, to serve as Chief Business Officer.
- Executive Compensation (Mr. Saxena):
- Annual base salary: $470,000.
- Target annual bonus: Up to 40% of base salary.
- Equity grants: 192,300 stock options (vesting 25% after one year, then monthly over 36 months) and 58,300 restricted stock units (vesting 25% annually over four years).
- Severance: 12 months of base salary for termination without cause/good reason (18 months during a Change in Control Period), plus COBRA coverage and potential pro-rated bonus.
- Board Appointment and Compensation: Brent Pfeiffenberger was appointed to the Board of Directors on May 19, 2026. He received initial equity awards consisting of 24,700 nonqualified stock options and 7,500 restricted stock units, both vesting in three equal annual installments.
- Upcoming Clinical Data: Management announced a conference call on May 26, 2026, to discuss clinical data from the Phase 1/2 study of CRB-701.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or updated operational outlook beyond the scheduled discussion of Phase 1/2 clinical data for CRB-701. Key contingencies include:
- Equity Vesting Conditions: All equity awards for Mr. Saxena and Dr. Pfeiffenberger are subject to continuous employment or service through specific vesting dates.
- Change in Control Provisions: Severance and accelerated vesting for Mr. Saxena are triggered by a Change in Control, defined as the period within six months preceding or twelve months following such an event.
- Excise Tax Reduction: Severance payments may be reduced to avoid excise taxes under Internal Revenue Code Section 4999.
Investor Verification Checklist
- Verify the closing stock price on May 21, 2026, to determine the exercise price for Mr. Saxena's 192,300 stock options.
- Confirm the specific vesting schedule and performance metrics for the 40% target bonus component of Mr. Saxena's compensation.
- Review the upcoming May 26, 2026, conference call materials for the Phase 1/2 CRB-701 clinical data results.
- Check the Company's 2024 Equity Incentive Plan (Exhibit 10.2) for remaining share availability following these new grants.